Dr. Youxiang Hou 侯友翔
Chief Physician, Associate Professor
Department of Gynecologic Radiation Oncology (Ward 1), Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy, chemotherapy, targeted therapy, and immunotherapy for gynecologic tumors, including cervical, vulvar, vaginal, and uterine body cancers, as well as recurrent and metastatic disease.
Dr. Hou is a Chief Physician, Associate Professor, and oncology postdoctoral fellow at the Affiliated Cancer Hospital of Xinjiang Medical University. With twelve years of experience in gynecologic oncology, Dr. Hou leads the Gynecologic Radiotherapy Ward 1. Research includes two National Natural Science Foundation projects. Publications include four SCI papers. Translated the Chinese version of ICRU Report 89.
Professional roles
- Member, Chinese Medical Association
- Youth Committee Member, Radiation Oncology Branch, Chinese Medical Association
- Standing Committee Member, Radiotherapy Professional Committee, Xinjiang Anti-Cancer Association
- Council Member, Western Radiation Therapy Association
Name order: in Chinese the family name comes first (Hou Youxiang). Papers usually list the name as Youxiang Hou or Hou Y.
Selected publications
9 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMJ Open, 2025 (senior author): p16 expression and its correlation with the clinical pathological characteristics of patients with cervical cancer: a systematic review and meta-analysis. PubMed 40940054
- Heliyon, 2024 (senior author): CD133(+)/ABCC5(+) cervical cancer cells exhibit cancer stem cell properties. PubMed 39296204
- Bioengineered, 2022 (senior author): Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma. PubMed 35192432
- Biomed Res Int, 2022 (first author): FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription. PubMed 35141332
- Cell Death Dis, 2017 (first author): The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. PubMed 28277541
- Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2016 (first author): [Pathogenic bacterium and drug resistance in cervical cancer patients complicated with reproductive tract infection]. PubMed 27592578
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion